ESMO Annual Congress

Additional prospective trials containing a larger sample size and longer follow up are needed to determine the optimal treatment sequence in favorable-risk advanced renal cell carcinoma.

The retrospective cohort study assessed outcomes in patients with advanced renal cell carcinoma who received cabozantinib or axitinib in the second-line setting or beyond.

The dual immunotherapy regimen maintained a survival benefit over single-agent sunitinib in patients with advanced renal cell carcinoma.

"Clinical benefit was observed regardless of homologous recombination repair gene mutational status," the study authors wrote.

The TKI/immunotherapy combination demonstrated strong clinical activity in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations.

The findings come from an exploratory subgroup analysis of the pivotal CheckMate 9-ER trial shared during the 2021 ESMO Congress.

Patients with VHL-mutated ccRCC and VHL–wild type disease often had low positive PD-L1 expression.

“Understanding the burden and time course of adverse events commonly associated with ARIs that may impact patients’ daily life will help inform optimal treatment selection for men with nmCRPC,” explained Christian Gratzke, MD.

“This indicates opportunities to improve communication about diagnosis, psychosocial impacts, and clinical trials, as well as biopsies, physical exercise, and patient engagement,” wrote Rachel H. Giles, PhD, and colleagues.

The findings showed a benefit for the immunotherapy/TKI regimen over sunitinib in adjusted overall survival as well as in the type and timing of subsequent therapy.

Episodic memory by computerized cognitive assessment was significantly improved in patients who received darolutamide compared with those treated with enzalutamide.

The risk was decreased further with each additional chemotherapy cycle a patient received.

Rucaparib pharmacokinetics in men with prostate cancer were comparable to those reported for women with ovarian cancer.

Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.

An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.

The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.

The addition of avelumab to standard first-line gemcitabine/carboplatin did not improve outcomes in patients with metastatic urothelial carcinoma.

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.

The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.

Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.

Pivotal phase 3 trial launched to confirm promising results in metastatic urothelial carcinoma.

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.